We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn RateSimplywall·1 day ago, 06:41 PM025750.00%
A Microcosm of Transition: How a Diverse Slate of Hong Kong Companies Navigates a Shifting EconomyGlobal Report·2 days ago, 04:44 AM09680-0.25%025750.00%
Hong Kong's Fragmented Signals: From Property Defense to Tech Capital RaisingsGlobal Report·Aug 11 at 04:43 AM06098+0.09%025750.00%
Hong Kong Mid-Caps Diverge: Biotech Expands Margins as Property Services Pivot to DefenseGlobal Report·Aug 5 at 04:13 AM01666-3.01%02497-2.34%
The Unbundling of Hong Kong's Equities: Value Chains in Specialized Tech and IndustrialsGlobal Report·Jul 30 at 04:13 AM08400-1.30%02302+2.75%
Xuanzhu Biopharma ordered to pay RMB 9.33 million in CIETAC arbitration awardPUBT·Jul 19 at 05:49 AM025750.00%
Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of AnaprazoleTip Ranks·Jun 29 at 11:38 PM00460-2.76%025750.00%
Xuanzhu Biopharma says NMPA accepts NDA for anaprazole sodium in reflux esophagitisPUBT·Jun 29 at 11:05 PM025750.00%
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori EradicationTip Ranks·Jun 21 at 05:38 AM025750.00%
Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradicationPUBT·Jun 21 at 05:05 AM025750.00%
Xuanzhu Biopharmaceutical files director list with Hong Kong Stock ExchangePUBT·Jun 18 at 05:25 AM025750.00%
